98 related articles for article (PubMed ID: 28620942)
1. A dose-escalation study of combretastatin A4-phosphate in healthy dogs.
Abma E; Smets P; Daminet S; Cornelis I; De Clercq K; Ni Y; Vlerick L; de Rooster H
Vet Comp Oncol; 2018 Mar; 16(1):E16-E22. PubMed ID: 28620942
[TBL] [Abstract][Full Text] [Related]
2. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.
Abma E; De Spiegelaere W; Vanderperren K; Stock E; Van Brantegem L; Cornelis I; Daminet S; Ni Y; Vynck M; Verstraete G; Smets P; de Rooster H
Vet Comp Oncol; 2018 Dec; 16(4):467-477. PubMed ID: 29797763
[TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours.
He X; Li S; Huang H; Li Z; Chen L; Ye S; Huang J; Zhan J; Lin T
Br J Clin Pharmacol; 2011 Jun; 71(6):860-70. PubMed ID: 21276042
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections.
Liu P; Qin Y; Wu L; Yang S; Li N; Wang H; Xu H; Sun K; Zhang S; Han X; Sun Y; Shi Y
Anticancer Drugs; 2014 Apr; 25(4):462-71. PubMed ID: 24500030
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer.
Cooney MM; Radivoyevitch T; Dowlati A; Overmoyer B; Levitan N; Robertson K; Levine SL; DeCaro K; Buchter C; Taylor A; Stambler BS; Remick SC
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):96-100. PubMed ID: 14734457
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of combretastatin a-4 phosphate with carboplatin.
Bilenker JH; Flaherty KT; Rosen M; Davis L; Gallagher M; Stevenson JP; Sun W; Vaughn D; Giantonio B; Zimmer R; Schnall M; O'Dwyer PJ
Clin Cancer Res; 2005 Feb; 11(4):1527-33. PubMed ID: 15746056
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck.
Ng QS; Mandeville H; Goh V; Alonzi R; Milner J; Carnell D; Meer K; Padhani AR; Saunders MI; Hoskin PJ
Ann Oncol; 2012 Jan; 23(1):231-237. PubMed ID: 21765046
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
Nathan P; Zweifel M; Padhani AR; Koh DM; Ng M; Collins DJ; Harris A; Carden C; Smythe J; Fisher N; Taylor NJ; Stirling JJ; Lu SP; Leach MO; Rustin GJ; Judson I
Clin Cancer Res; 2012 Jun; 18(12):3428-39. PubMed ID: 22645052
[TBL] [Abstract][Full Text] [Related]
10. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate.
Anderson HL; Yap JT; Miller MP; Robbins A; Jones T; Price PM
J Clin Oncol; 2003 Aug; 21(15):2823-30. PubMed ID: 12807935
[TBL] [Abstract][Full Text] [Related]
11. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.
Dowlati A; Robertson K; Cooney M; Petros WP; Stratford M; Jesberger J; Rafie N; Overmoyer B; Makkar V; Stambler B; Taylor A; Waas J; Lewin JS; McCrae KR; Remick SC
Cancer Res; 2002 Jun; 62(12):3408-16. PubMed ID: 12067983
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats.
Ke Q; Bodyak N; Rigor DL; Hurst NW; Chaplin DJ; Kang PM
Vascul Pharmacol; 2009; 51(5-6):337-43. PubMed ID: 19737629
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
Meyer T; Gaya AM; Dancey G; Stratford MR; Othman S; Sharma SK; Wellsted D; Taylor NJ; Stirling JJ; Poupard L; Folkes LK; Chan PS; Pedley RB; Chester KA; Owen K; Violet JA; Malaroda A; Green AJ; Buscombe J; Padhani AR; Rustin GJ; Begent RH
Clin Cancer Res; 2009 Jul; 15(13):4484-92. PubMed ID: 19549771
[TBL] [Abstract][Full Text] [Related]
14. Exaggerated hypertensive response to combretastatin A-4 phosphate in hypertensive rats: Effective pharmacological inhibition by diltiazem.
Ke Q; Samad MA; Bae S; Chaplin DJ; Kang PM
Vascul Pharmacol; 2015 Nov; 74():73-79. PubMed ID: 25989107
[TBL] [Abstract][Full Text] [Related]
15. The vascular-disrupting agent, combretastatin-A4-phosphate, enhances neurogenic vasoconstriction in rat small arteries.
Su J; Laursen BE; Eskildsen-Helmond Y; Horsman MR; Simonsen U
Eur J Pharmacol; 2012 Nov; 695(1-3):104-11. PubMed ID: 22981665
[TBL] [Abstract][Full Text] [Related]
16. Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma.
Badn W; Kalliomäki S; Widegren B; Sjögren HO
Clin Cancer Res; 2006 Aug; 12(15):4714-9. PubMed ID: 16899622
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Cardiotoxicity after a Single Dose of Combretastatin A4-Phosphate in Dogs Using Two-Dimensional Speckle-Tracking Echocardiography.
Mampaey G; Hellemans A; de Rooster H; Schipper T; Abma E; Broeckx BJG; Daminet S; Smets P
Animals (Basel); 2022 Nov; 12(21):. PubMed ID: 36359129
[TBL] [Abstract][Full Text] [Related]
18. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
[TBL] [Abstract][Full Text] [Related]
19. Vascular disrupting effects of combretastatin A4 phosphate on murine endometriotic lesions.
Feng D; Menger MD; Laschke MW
Fertil Steril; 2013 Nov; 100(5):1459-67. PubMed ID: 23993929
[TBL] [Abstract][Full Text] [Related]
20. Concentration-Induced J-Aggregate Formation Causes a Biphasic Change in the Release of trans-Combretastatin A4 Disodium Phosphate from Archaeosomes and the Subsequent Cytotoxicity on Mammary Cancer Cells.
Daswani VP; Ayesa U; Venegas B; Chong PL
Mol Pharm; 2015 Oct; 12(10):3724-34. PubMed ID: 26355665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
